Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Biocytogen

Biocytogen

Biocytogen is a Wakefield, Massachusetts-based biotechnology company developing antibody drug discovery solutions based on gene editing and animal model studies.

Biocytogen engages in the development of antibody drug discovery solutions based on gene editing technologies and animal model research. The company was founded in 2009 and is headquartered in Wakefield, Massachusetts.

Beijing Biocytogen is a biotechnology company focused on antibody discovery, disease models, and preclinical testing. The company partners with research scientists in the biomedical industry to provide gene editing services, animal disease models, and antibody development services.

Timeline

February 25, 2021
Biocytogen announces acquisition of a third Beacon Optofluidic system.
September 15, 2020
Biocytogen raises a $150,000,000 series D round from 3E Bioventures Capital, Baidu Capital, CMB International Capital Corporation, Cowin Capital and SDIC Venture Capital.
September 2020
Biocytogen raises a $142,000,000 series D round from 3E Bioventures Capital, Baidu Capital, CMB International Capital Corporation, China Life Private Equity Investment Co, Cowin Capital, PICC Capital and SDIC Venture Capital.
August 8, 2019
Biocytogen raises a $84,000,000 series D round from 3E Bioventures Capital, CMB International Capital Corporation and SDIC Venture Capital.
April 10, 2018
Biocytogen raises a $63,400,000 series C round from 3E Bioventures Capital, CMB International Capital Corporation, Cowin Capital, Oriza Holdings and SDIC Venture Capital.
April 2018
Biocytogen raises a $63,105,068 series C round from 3E Bioventures Capital, CMB International Capital Corporation, Cowin Capital, Oriza Holdings and SDIC Venture Capital.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Biocytogen
June 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, ein internationales Biotechnologieunternehmen, das sich auf die Erforschung und Entwicklung von Antikörpermedikamenten unter...
Biocytogen
June 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, une société internationale de biotechnologie spécialisée dans la recherche et le développement (R&D) de médicaments à base...
Biocytogen
June 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, una empresa internacional de biotecnología centrada en la investigación y el desarrollo (I+D) de fármacos de anticuerpos utilizando...
Biocytogen
June 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically...
Biocytogen
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, ein Unternehmen, das sich der Beschleunigung der Entdeckung therapeutischer Antikörper widmet, hat den Erwerb eines dritten Beacon...
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.